Eli Lilly Surpasses $1.1 Trillion Market Value on Weight-Loss Drug Momentum

2026-10-17 companies

Indianapolis, Saturday, 17 October 2026.
Eli Lilly eclipsed Berkshire Hathaway to enter the top ten U.S. companies by market value, driven by booming demand for its weight-loss therapies and strong revenue growth.

Market Capitalization and Trading Performance

Eli Lilly and Company (NYSE: LLY) has officially overtaken Berkshire Hathaway to become the 10th-largest U.S. company by market capitalization, a milestone driven by a 4.94% jump in stock price to $1,268 [5]. As of the market close on 16 October 2026, shares traded at $1,257.03, reflecting a daily increase of $5.42 or 0.43% [2][3]. The company’s market capitalization stands at approximately $1.183 trillion, calculated using 941.36 million shares outstanding and a closing price of $1,257.03 1183.318 [3]. This valuation places the stock near the top of its 52-week range, with a high of $1,292.65 recorded on 19 August 2026 [3][6]. Over the past year leading to 16 October 2026, the stock performance metrics indicate an increase of 95.93%, demonstrating significant investor confidence despite periodic volatility [4]. Recent trading activity shows a 1-month gain of 10.48% and a 1-week gain of 6.59% as of 16 October 2026 [1]. The stock has experienced notable volatility, with a 3-year low of $547.61 and a 10-year low of $64.18, highlighting the magnitude of its recent appreciation [1]. After-hours trading on 16 October 2026 showed a slight decline of $1.02, indicating continued market scrutiny [4].

Revenue Drivers and GLP-1 Market Dominance

The pharmaceutical giant’s valuation is heavily underpinned by its dominance in the GLP-1 weight-loss and diabetes treatment sector, where it maintains a 60% market share in the United States [2][4]. Endocrinology products account for 74% of Eli Lilly’s net sales by therapeutic field, making it the primary revenue engine [1]. Revenue projections indicate net sales of $88.5 billion for 2026 and $102 billion for 2027, supported by high demand for drugs such as Mounjaro and Zepbound [1][2]. The broader GLP-1 market is projected to reach nearly $100 billion by 2030, suggesting sustained growth potential [2]. Recent regulatory developments include the European Medicines Agency (EMA) adopting a positive opinion for Eli Lilly’s Foundayo on 15 October 2026, recommending approval for the new weight-loss drug [4]. However, supply chain concerns have emerged, with reports on 15 October 2026 indicating mold and bug contamination at Chinese factories manufacturing components for GLP-1 medications [4]. Despite these challenges, the company continues to expand its pipeline, initiating a Phase 2 trial targeting KRAS G12C in colorectal cancer and commencing a new Alzheimer’s study for Donanemab in India on 15 October 2026 [4].

Valuation Metrics and Future Outlook

Investors are closely analyzing valuation metrics, with Eli Lilly’s 2026 P/E ratio estimated at 36x and the 2027 P/E ratio at 27.9x [1]. The 2026 EV/Sales ratio stands at 13x, decreasing to 11x in 2027, indicating expected efficiency improvements [1]. Market speculation regarding a potential stock split has intensified due to the share price exceeding the $1,000 psychological barrier, although no official announcement has been made as of 17 October 2026 [2]. Historically, Eli Lilly has executed four stock splits, with the most recent occurring nearly 30 years ago [2]. Financial analysts remain broadly positive, with RBC Capital initiating a ‘Buy’ rating and Wells Fargo reaffirming its existing ‘Buy’ rating on 15 October 2026 [4]. Consensus price targets range from $930.00 to $1,600.00, reflecting a wide range of expectations [8]. The company is scheduled to report earnings on 29 October 2026, a key event for validating current projections [3]. Net income is projected at $31.21 billion for 2026 and $40.35 billion for 2027, supporting the bullish outlook despite the high valuation multiples [1].

Sources

Pharmaceuticals Valuation